Literature DB >> 14996674

Factor V Leiden and the risk for venous thromboembolism in the adult Danish population.

Klaus Juul1, Anne Tybjaerg-Hansen, Peter Schnohr, Børge G Nordestgaard.   

Abstract

BACKGROUND: Odds ratios for venous thromboembolism (deep venous thrombosis and pulmonary embolism) derived from case-control studies range from 3 to 16 for heterozygotes compared with noncarriers and up to 79 for homozygotes compared with noncarriers.
OBJECTIVE: To estimate risks for venous thromboembolism in the adult Danish population according to factor V Leiden genotype.
DESIGN: Cohort study with 23 years of follow-up.
SETTING: Adult Danish population. PARTICIPANTS: 9253 randomly selected individuals. MEASUREMENTS: Hospitalization and death from venous thromboembolism, factor V Leiden genotype, and additional thromboembolic risk factors.
RESULTS: Adjusted hazard ratios in heterozygotes and homozygotes compared with noncarriers were 2.7 (95% CI, 1.8 to 3.8) and 18 (CI, 4.1 to 41) for venous thromboembolism overall, 2.4 (CI, 1.3 to 3.8) and 22 (CI, 0 to 60) for deep venous thrombosis, and 3.0 (CI, 1.7 to 4.9) and 11 (CI, 0 to 33) for pulmonary embolism. The lowest absolute 10-year risks for venous thromboembolism in factor V Leiden heterozygotes and homozygotes--0.7% (CI, 0.5% to 1.0%) and 3% (CI, 1% to 8%)--were found in nonsmokers younger than 40 years of age with a body mass index below 25 kg/m2; the corresponding highest risks--10% (CI, 7% to 14%) and 51% (CI, 13% to 100%)--were found in smokers older than 60 years of age with a body mass index above 30 kg/m2.
CONCLUSIONS: Hazard ratios for venous thromboembolism in factor V Leiden heterozygotes and homozygotes compared with noncarriers in the adult Danish population were approximately 3 and 18, respectively. The simultaneous presence of smoking, obesity, and old age resulted in absolute 10-year thromboembolic risks of 10% in heterozygotes and 51% in homozygotes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996674     DOI: 10.7326/0003-4819-140-5-200403020-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  33 in total

Review 1.  Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox.

Authors:  Javier Corral; Vanessa Roldán; Vicente Vicente
Journal:  Haematologica       Date:  2010-06       Impact factor: 9.941

Review 2.  Thrombophilia: clinical-practical aspects.

Authors:  Stephan Moll
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

3.  Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems.

Authors:  Christoph Lichy; Tuan Dong-Si; Karl Reuner; Just Genius; Henning Rickmann; Toni Hampe; Tarah Dolan; Felix Stoll; Armin Grau
Journal:  J Neurol       Date:  2005-09-16       Impact factor: 4.849

4.  Phlegmasia cerulea dolens in a teenage boy found to have Factor V Leiden.

Authors:  Emily Junck; Sachita Shah
Journal:  BMJ Case Rep       Date:  2015-04-02

5.  Usefulness of factor V Leiden mutation testing in clinical practice.

Authors:  Ellen Ø Blinkenberg; Ann-Helen Kristoffersen; Sverre Sandberg; Vidar M Steen; Gunnar Houge
Journal:  Eur J Hum Genet       Date:  2010-03-24       Impact factor: 4.246

Review 6.  Genetics in the context of thrombophilia.

Authors:  Elizabeth A Varga
Journal:  J Thromb Thrombolysis       Date:  2007-10-19       Impact factor: 2.300

7.  Upper-extremity deep-vein thrombosis in an elderly man.

Authors:  Ofir Har-Noy; Eyal Meltzer
Journal:  CMAJ       Date:  2007-04-10       Impact factor: 8.262

Review 8.  Can haemostatic factors predict atherothrombosis?

Authors:  Gordon Lowe
Journal:  Intern Emerg Med       Date:  2011-02-15       Impact factor: 3.397

Review 9.  Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders.

Authors:  Frauke Becker; Carla G van El; Dolores Ibarreta; Eleni Zika; Stuart Hogarth; Pascal Borry; Anne Cambon-Thomsen; Jean Jacques Cassiman; Gerry Evers-Kiebooms; Shirley Hodgson; A Cécile J W Janssens; Helena Kaariainen; Michael Krawczak; Ulf Kristoffersson; Jan Lubinski; Christine Patch; Victor B Penchaszadeh; Andrew Read; Wolf Rogowski; Jorge Sequeiros; Lisbeth Tranebjaerg; Irene M van Langen; Helen Wallace; Ron Zimmern; Jörg Schmidtke; Martina C Cornel
Journal:  Eur J Hum Genet       Date:  2011-04       Impact factor: 4.246

10.  Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin.

Authors:  D M O Pruissen; F R Rosendaal; J W Gorter; A A Garcia; L J Kappelle; A Algra
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.